Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT04402905 |
Other study ID # |
CREPATS 011 |
Secondary ID |
|
Status |
Completed |
Phase |
|
First received |
|
Last updated |
|
Start date |
June 15, 2020 |
Est. completion date |
August 15, 2020 |
Study information
Verified date |
February 2021 |
Source |
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
COVID-19 is an infection linked to a new coronavirus: SARS-CoV-2, which appeared in Wuhan in
China at the end of 2019, and which has since spread around the world, responsible for a new
major pandemic, which is upsetting the whole world.
If severe respiratory disease is the form that constitutes the extreme gravity of the disease
(mortality, with more than 170,000 deaths worldwide to date).
However, there is a great heterogeneity of clinical forms with asymptomatic or symptomatic
pauci forms, moderate forms, up to severe forms.
Different symptoms may appear: fever, cough, asthenia, dyspnea, gastrointestinal forms,
anosmia and / or ageusia, skin involvement, etc.
Given the novelty of this infection, several questions remain:
- What are all the symptoms that can be contracted by a COVID-19 patient?
- Are there clinical forms not described?
- What is the evolutionary profile, the healing time of this disease in patients treated
on an outpatient basis?
- What are the factors associated with a prolonged form of COVID-19 disease, including on
an outpatient basis?
Description:
Most of the descriptive studies relating to COVID-19 relate to the severe forms of the
disease managed in the hospital sector.
Few data have been published on moderate forms, requiring no hospitalization, of strict
outpatient management.
These so-called moderate forms, however, constitute the majority of cases of COVID-19
(approximately 80%).
In the Infectious and Tropical Diseases Department of Pitie Salpetriere, COVIDOM pilot site,
at the beginning of March, during the intensification of the epidemic in France, a weekly
telephone consultation was set up to take care of people tested for COVID + by PCR, or people
not tested by PCR, or even tested with negative PCR but symptomatic and followed at home,
suffering from moderate form of COVID-19, as well as their contact cases if they wished.
Telemedicine is particularly suitable in this epidemic context, ensuring continuity of care,
while limiting face-to-face consultations, thus reducing the risk of cross-contamination.
Given the novelty of this infection, it is important to be able to best characterize these
ambulatory forms, as well as their evolution, in order to manage these patients, and to offer
primary care physicians a more detailed description of these forms. , which they are and will
be called upon to take care of, general medicine being central to dealing with the epidemic.